Sequencing paediatric antiretroviral therapy in the context of a public health approach

Ragna S. Boerma, T. Sonia Boender, Michael Boele Van Hensbroek, Tobias F.Rinke De Wit, Kim C.E. Sigaloff

Research output: Contribution to journalReview articleAcademicpeer-review

9 Citations (Scopus)


Introduction: As access to prevention of mother-to-child transmission (PMTCT) efforts has increased, the total number of children being born with HIV has significantly decreased. However, those children who do become infected after PMTCT failure are at particular risk of HIV drug resistance, selected by exposure to maternal or paediatric antiretroviral drugs used before, during or after birth. As a consequence, the response to antiretroviral therapy (ART) in these children may be compromised, particularly when non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used as part of the first-line regimen. We review evidence guiding choices of first- and second-line ART. Discussion: Children generally respond relatively well to ART. Clinical trials show the superiority of protease inhibitor (PI)- over NNRTI-based treatment in young children, but observational reports of NNRTI-containing regimens are usually favourable as well. This is reassuring as national guidelines often still recommend the use of NNRTI-based treatment for PMTCT-unexposed young children, due to the higher costs of PIs. After failure of NNRTI-based, first-line treatment, the rate of acquired drug resistance is high, but HIV may well be suppressed by PIs in second-line ART. By contrast, there are currently no adequate alternatives in resource-limited settings (RLS) for children failing either first- or second-line, PI-containing regimens. Conclusions: Affordable salvage treatment options for children in RLS are urgently needed.

Original languageEnglish
Article number20265
Pages (from-to)24-29
JournalJournal of the International AIDS Society
Issue number6
Publication statusPublished - 2 Dec 2015


  • Antiretroviral therapy
  • HIV drug resistance
  • Non-nucleoside reverse transcriptase inhibitor; low- and middle-income countries
  • Paediatric HIV
  • Protease inhibitor

Cite this